NCT00815295 - Study of Sorafenib/Cetuximab in Head and Neck Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions

Squamous Cell Cancer

Interventions

DRUG

Sorafenib

Phase 1 - Dose level 1 : Sorafenib will be given 200 mg twice daily oral, Phase 1 - Dose level 2 : Sorafenib will be given 400 mg twice daily oral, Phase 2 : Sorafenib will be given at the maximum tolerated dose from Phase 1

DRUG

Cetuximab

Cetuximab will be given at standard approved dose: 400 mg/m2 loading dose followed by 250 mg/m2 weekly.

Trial Locations (1)

27710

Duke University Health System, Durham